Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo

BACKGROUND AND PURPOSE: Bendamustine with or without rituximab provides an effective and more tolerable alternative to the polytherapy cyclophosphamide–doxorubicin–vincristine–prednisolone (CHOP) in the treatment of haematological tumours and is currently approved for the treatment of many haematolo...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ackler, S, Mitten, MJ, Chen, J, Clarin, J, Foster, K, Jin, S, Phillips, DC, Schlessinger, S, Wang, B, Leverson, JD, Boghaert, ER
Format: Artigo
Langue:Inglês
Publié: Blackwell Publishing Ltd 2012
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3575786/
https://ncbi.nlm.nih.gov/pubmed/22624727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1476-5381.2012.02048.x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires